Upon excluding direct thrombin inhibitors, specifically dabigatran, the analysis revealed that inhibitors targeting thrombin and factor X can further diminish the occurrence of stroke or systemic embolism, all-cause mortality, massive bleeding, and fatal bleeding in patients with CKD. Here, F10 is linked to chronic kidney disease.